Abstract
Fifteen novel biphenyl-N-heterocyclic carbene (NHC)-gold(I) complexes were designed and synthesized to treat ovarian cancer (OC). Among these, complex Au-1 showed significant antiproliferative activity against A2780 cells and A2780/CDDP cells. Notably, Au-1 exhibited low toxicity to normal ovarian epithelial IOSE-80 cells. Further studies revealed that Au-1 strongly inhibited thioredoxin reductase (TrxR) activity. Collectively, our results demonstrated that Au-1 could be a promising candidate for the treatment of OC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
